Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ana Meekins

Urogynecology and Reconstructive Pelvic Surgery Durham, NC Medical Doctor

NPI 1760725592 CMS profile 5661980

2301 Erwin Rd, Durham, NC 27705

Open in the dashboard

General payments

$6,978

295 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Meekins of Durham, NC is reported in the CMS Open Payments database as having received $6,978 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,354 50
2024 General $1,455 61
2023 General $2,365 89
2022 General $1,128 57
2021 General $637 36
2020 General $39 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Meekins
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Ana Meekins were reported at $1,354. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Ana Meekins Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $358 $132–$1,270 $163
2020 $39 $198 $86–$642 $114
2021 $637 $361 $118–$1,182 $132
2022 $1,128 $410 $128–$1,175 $149
2023 $2,365 $434 $152–$1,344 $160
2024 $1,455 $494 $193–$1,331 $164
2025 $1,354 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,371 46 payments
  2. Axonics Modulation Technologies, Inc. $1,023 32 payments
  3. Sumitomo Pharma America, Inc. $926 47 payments
  4. Dendreon Pharmaceuticals LLC $731 25 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $486 21 payments
  6. Blue Earth Diagnostics Limited $207 9 payments
  7. Accord Healthcare, Inc. $198 10 payments
  8. Endo Pharmaceuticals Inc. $197 12 payments
  9. Urogen Pharma, Inc. $195 8 payments
  10. Merck Sharp & Dohme Corporation $179 8 payments
  11. Other $1,465 77 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,682 294 payments
  2. Honoraria $295 1 payment
Products named General payments · program years 2020–2025
  1. Axonics $1,072 33 payments
  2. BOTOX Botox Therapeutic $1,053 40 payments
  3. GEMTESA $991 51 payments
  4. PROVENGE $731 25 payments
  5. Nubeqa $486 21 payments
  6. Xofigo $413 18 payments
  7. XIAFLEX $288 16 payments
  8. BOTOX Urology $254 3 payments
  9. AVEED $205 12 payments
  10. CAMCEVI $158 8 payments
  11. Other $2,251 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

2,686

Median for Obstetrics & Gynecology: 65

Drug cost

$745,343

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

50.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 580 $450,920
Myrbetriq Mirabegron Brand 279 $178,583
Estradiol Generic 400 $27,108
Mirabegron Er Mirabegron Brand 44 $24,694
Methenamine Hippurate Generic 220 $17,351
Trospium Chloride Generic 210 $13,946
Trospium Chloride Er Trospium Chloride Brand 108 $13,825
Fosfomycin Tromethamine Generic 33 $8,328
Trimethoprim Generic 60 $3,494
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 215 $3,169

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$327,491

Of which drugs: $71,845

Medicare patients

1,075

Average age 77

Services billed

19,991

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Depression 30%
Osteoporosis 27%
Diabetes 25%
Ischemic heart disease 24%
Chronic kidney disease 24%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 93 14,600 $71,844

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $429
$429 — 14,600
GEMTESA
  • Sumitomo Pharma America, Inc. $278
$278 580 —
XIAFLEX
  • Endo USA, Inc. $65
  • Endo Pharmaceuticals Inc. $28
$93 — —
POSLUMA
  • Blue Earth Diagnostics Limited $65
$65 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record